nodes	percent_of_prediction	percent_of_DWPC	metapath
Perhexiline—CYP2B6—Cholecalciferol—psoriasis	0.106	0.157	CbGbCtD
Perhexiline—CYP2D6—Hydroxyurea—psoriasis	0.0846	0.125	CbGbCtD
Perhexiline—CYP3A4—Calcitriol—psoriasis	0.0633	0.0938	CbGbCtD
Perhexiline—CYP2D6—Cholecalciferol—psoriasis	0.0512	0.076	CbGbCtD
Perhexiline—CYP3A4—Methoxsalen—psoriasis	0.0492	0.073	CbGbCtD
Perhexiline—CYP2B6—Dexamethasone—psoriasis	0.0459	0.0681	CbGbCtD
Perhexiline—CYP2D6—Cyclosporine—psoriasis	0.0337	0.05	CbGbCtD
Perhexiline—CYP3A4—Cholecalciferol—psoriasis	0.0326	0.0483	CbGbCtD
Perhexiline—CYP3A4—Triamcinolone—psoriasis	0.0283	0.0419	CbGbCtD
Perhexiline—CYP3A4—Mycophenolate mofetil—psoriasis	0.0283	0.0419	CbGbCtD
Perhexiline—CYP3A4—Betamethasone—psoriasis	0.0242	0.036	CbGbCtD
Perhexiline—CYP3A4—Prednisolone—psoriasis	0.0239	0.0355	CbGbCtD
Perhexiline—CYP3A4—Hydrocortisone—psoriasis	0.0227	0.0336	CbGbCtD
Perhexiline—CYP3A4—Prednisone—psoriasis	0.0226	0.0335	CbGbCtD
Perhexiline—CYP2D6—Dexamethasone—psoriasis	0.0222	0.0329	CbGbCtD
Perhexiline—CYP3A4—Cyclosporine—psoriasis	0.0214	0.0318	CbGbCtD
Perhexiline—CYP3A4—Dexamethasone—psoriasis	0.0141	0.0209	CbGbCtD
Perhexiline—CPT1A—RORA activates circadian gene expression—CARM1—psoriasis	0.00484	0.0772	CbGpPWpGaD
Perhexiline—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00453	0.0721	CbGpPWpGaD
Perhexiline—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00315	0.0501	CbGpPWpGaD
Perhexiline—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00293	0.0467	CbGpPWpGaD
Perhexiline—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00281	0.0447	CbGpPWpGaD
Perhexiline—CPT1A—Circadian Clock—CARM1—psoriasis	0.00258	0.0411	CbGpPWpGaD
Perhexiline—CPT2—PPARA activates gene expression—CARM1—psoriasis	0.00214	0.034	CbGpPWpGaD
Perhexiline—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00209	0.0333	CbGpPWpGaD
Perhexiline—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00195	0.0311	CbGpPWpGaD
Perhexiline—CPT1A—PPARA activates gene expression—CARM1—psoriasis	0.00148	0.0236	CbGpPWpGaD
Perhexiline—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00145	0.0231	CbGpPWpGaD
Perhexiline—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.00144	0.0229	CbGpPWpGaD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00132	0.021	CbGpPWpGaD
Perhexiline—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00128	0.0203	CbGpPWpGaD
Perhexiline—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00117	0.0186	CbGpPWpGaD
Perhexiline—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00115	0.0183	CbGpPWpGaD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—IL13—psoriasis	0.00104	0.0166	CbGpPWpGaD
Perhexiline—CPT1A—AMPK Signaling—LEP—psoriasis	0.00103	0.0164	CbGpPWpGaD
Perhexiline—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000999	0.0159	CbGpPWpGaD
Perhexiline—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000945	0.015	CbGpPWpGaD
Perhexiline—CPT2—PPARA activates gene expression—PPARG—psoriasis	0.000889	0.0142	CbGpPWpGaD
Perhexiline—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.00087	0.0139	CbGpPWpGaD
Perhexiline—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00081	0.0129	CbGpPWpGaD
Perhexiline—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000799	0.0127	CbGpPWpGaD
Perhexiline—Gastrointestinal pain—Acitretin—psoriasis	0.000702	0.00267	CcSEcCtD
Perhexiline—Neuropathy peripheral—Cyclosporine—psoriasis	0.000702	0.00267	CcSEcCtD
Perhexiline—Asthenia—Calcitriol—psoriasis	0.000693	0.00263	CcSEcCtD
Perhexiline—Muscular weakness—Triamcinolone—psoriasis	0.000686	0.00261	CcSEcCtD
Perhexiline—Neuropathy peripheral—Mycophenolate mofetil—psoriasis	0.000685	0.0026	CcSEcCtD
Perhexiline—Rash—Methoxsalen—psoriasis	0.000683	0.0026	CcSEcCtD
Perhexiline—Dermatitis—Methoxsalen—psoriasis	0.000682	0.00259	CcSEcCtD
Perhexiline—Urticaria—Acitretin—psoriasis	0.000682	0.00259	CcSEcCtD
Perhexiline—Tension—Mycophenolic acid—psoriasis	0.000679	0.00258	CcSEcCtD
Perhexiline—Abdominal pain—Acitretin—psoriasis	0.000679	0.00258	CcSEcCtD
Perhexiline—Headache—Methoxsalen—psoriasis	0.000679	0.00258	CcSEcCtD
Perhexiline—Nervousness—Mycophenolic acid—psoriasis	0.000672	0.00255	CcSEcCtD
Perhexiline—Sweating—Mycophenolate mofetil—psoriasis	0.00067	0.00255	CcSEcCtD
Perhexiline—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000657	0.0105	CbGpPWpGaD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—IL10—psoriasis	0.00065	0.0104	CbGpPWpGaD
Perhexiline—Tremor—Mycophenolic acid—psoriasis	0.000648	0.00246	CcSEcCtD
Perhexiline—Weight decreased—Hydrocortisone—psoriasis	0.000646	0.00246	CcSEcCtD
Perhexiline—Nausea—Methoxsalen—psoriasis	0.000644	0.00245	CcSEcCtD
Perhexiline—Hepatitis—Cyclosporine—psoriasis	0.000643	0.00244	CcSEcCtD
Perhexiline—Anorexia—Hydroxyurea—psoriasis	0.000643	0.00244	CcSEcCtD
Perhexiline—Neuropathy peripheral—Prednisolone—psoriasis	0.000639	0.00243	CcSEcCtD
Perhexiline—Hepatitis—Mycophenolate mofetil—psoriasis	0.000627	0.00238	CcSEcCtD
Perhexiline—Neuropathy peripheral—Hydrocortisone—psoriasis	0.000624	0.00237	CcSEcCtD
Perhexiline—Muscular weakness—Dexamethasone—psoriasis	0.000623	0.00237	CcSEcCtD
Perhexiline—Muscular weakness—Betamethasone—psoriasis	0.000623	0.00237	CcSEcCtD
Perhexiline—Syncope—Mycophenolic acid—psoriasis	0.000621	0.00236	CcSEcCtD
Perhexiline—Asthenia—Acitretin—psoriasis	0.000616	0.00234	CcSEcCtD
Perhexiline—CPT1A—PPARA activates gene expression—PPARG—psoriasis	0.000616	0.00982	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—NDUFA5—psoriasis	0.000615	0.0098	CbGpPWpGaD
Perhexiline—Vomiting—Calcitriol—psoriasis	0.000614	0.00233	CcSEcCtD
Perhexiline—Rash—Calcitriol—psoriasis	0.000609	0.00231	CcSEcCtD
Perhexiline—Loss of consciousness—Mycophenolic acid—psoriasis	0.000608	0.00231	CcSEcCtD
Perhexiline—Dermatitis—Calcitriol—psoriasis	0.000608	0.00231	CcSEcCtD
Perhexiline—Headache—Calcitriol—psoriasis	0.000605	0.0023	CcSEcCtD
Perhexiline—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000603	0.00961	CbGpPWpGaD
Perhexiline—Convulsion—Mycophenolic acid—psoriasis	0.0006	0.00228	CcSEcCtD
Perhexiline—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.0006	0.00955	CbGpPWpGaD
Perhexiline—Flushing—Cyclosporine—psoriasis	0.000597	0.00227	CcSEcCtD
Perhexiline—Neuropathy peripheral—Triamcinolone—psoriasis	0.000588	0.00223	CcSEcCtD
Perhexiline—Decreased appetite—Hydroxyurea—psoriasis	0.000586	0.00223	CcSEcCtD
Perhexiline—Fatigue—Hydroxyurea—psoriasis	0.000581	0.00221	CcSEcCtD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000574	0.00914	CbGpPWpGaD
Perhexiline—Nausea—Calcitriol—psoriasis	0.000574	0.00218	CcSEcCtD
Perhexiline—Dizziness—Acitretin—psoriasis	0.000568	0.00216	CcSEcCtD
Perhexiline—Dizziness—Fluocinolone Acetonide—psoriasis	0.000566	0.00215	CcSEcCtD
Perhexiline—Shock—Mycophenolic acid—psoriasis	0.000556	0.00211	CcSEcCtD
Perhexiline—Weight decreased—Dexamethasone—psoriasis	0.000552	0.0021	CcSEcCtD
Perhexiline—Weight decreased—Betamethasone—psoriasis	0.000552	0.0021	CcSEcCtD
Perhexiline—Tension—Cyclosporine—psoriasis	0.000549	0.00209	CcSEcCtD
Perhexiline—Vomiting—Acitretin—psoriasis	0.000546	0.00208	CcSEcCtD
Perhexiline—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000546	0.00208	CcSEcCtD
Perhexiline—Vomiting—Fluocinolone Acetonide—psoriasis	0.000545	0.00207	CcSEcCtD
Perhexiline—Nervousness—Cyclosporine—psoriasis	0.000544	0.00207	CcSEcCtD
Perhexiline—Muscular weakness—Prednisone—psoriasis	0.000542	0.00206	CcSEcCtD
Perhexiline—Rash—Acitretin—psoriasis	0.000542	0.00206	CcSEcCtD
Perhexiline—Dermatitis—Acitretin—psoriasis	0.000541	0.00206	CcSEcCtD
Perhexiline—Rash—Fluocinolone Acetonide—psoriasis	0.00054	0.00205	CcSEcCtD
Perhexiline—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00054	0.00205	CcSEcCtD
Perhexiline—Anorexia—Mycophenolic acid—psoriasis	0.000538	0.00205	CcSEcCtD
Perhexiline—Headache—Acitretin—psoriasis	0.000538	0.00205	CcSEcCtD
Perhexiline—Headache—Fluocinolone Acetonide—psoriasis	0.000537	0.00204	CcSEcCtD
Perhexiline—Tension—Mycophenolate mofetil—psoriasis	0.000536	0.00204	CcSEcCtD
Perhexiline—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000535	0.00852	CbGpPWpGaD
Perhexiline—Neuropathy peripheral—Betamethasone—psoriasis	0.000533	0.00203	CcSEcCtD
Perhexiline—Neuropathy peripheral—Dexamethasone—psoriasis	0.000533	0.00203	CcSEcCtD
Perhexiline—Nervousness—Mycophenolate mofetil—psoriasis	0.000531	0.00202	CcSEcCtD
Perhexiline—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000529	0.00843	CbGpPWpGaD
Perhexiline—Tremor—Cyclosporine—psoriasis	0.000525	0.00199	CcSEcCtD
Perhexiline—CPT2—Metabolism—CYP2S1—psoriasis	0.000523	0.00833	CbGpPWpGaD
Perhexiline—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000523	0.00832	CbGpPWpGaD
Perhexiline—Tremor—Mycophenolate mofetil—psoriasis	0.000512	0.00194	CcSEcCtD
Perhexiline—Insomnia—Mycophenolic acid—psoriasis	0.000511	0.00194	CcSEcCtD
Perhexiline—Nausea—Acitretin—psoriasis	0.00051	0.00194	CcSEcCtD
Perhexiline—Nausea—Fluocinolone Acetonide—psoriasis	0.000509	0.00193	CcSEcCtD
Perhexiline—Paraesthesia—Mycophenolic acid—psoriasis	0.000507	0.00193	CcSEcCtD
Perhexiline—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000502	0.00799	CbGpPWpGaD
Perhexiline—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000495	0.00788	CbGpPWpGaD
Perhexiline—Decreased appetite—Mycophenolic acid—psoriasis	0.000491	0.00187	CcSEcCtD
Perhexiline—Syncope—Mycophenolate mofetil—psoriasis	0.00049	0.00186	CcSEcCtD
Perhexiline—Fatigue—Mycophenolic acid—psoriasis	0.000487	0.00185	CcSEcCtD
Perhexiline—Convulsion—Cyclosporine—psoriasis	0.000485	0.00184	CcSEcCtD
Perhexiline—Asthenia—Hydroxyurea—psoriasis	0.000484	0.00184	CcSEcCtD
Perhexiline—Ataxia—Methotrexate—psoriasis	0.000483	0.00184	CcSEcCtD
Perhexiline—Weight decreased—Prednisone—psoriasis	0.000481	0.00183	CcSEcCtD
Perhexiline—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.00048	0.00182	CcSEcCtD
Perhexiline—Convulsion—Mycophenolate mofetil—psoriasis	0.000473	0.0018	CcSEcCtD
Perhexiline—Neuropathy peripheral—Prednisone—psoriasis	0.000464	0.00176	CcSEcCtD
Perhexiline—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000462	0.00176	CcSEcCtD
Perhexiline—Syncope—Prednisolone—psoriasis	0.000457	0.00174	CcSEcCtD
Perhexiline—Loss of consciousness—Prednisolone—psoriasis	0.000448	0.0017	CcSEcCtD
Perhexiline—Abdominal pain—Mycophenolic acid—psoriasis	0.000447	0.0017	CcSEcCtD
Perhexiline—Syncope—Hydrocortisone—psoriasis	0.000446	0.0017	CcSEcCtD
Perhexiline—Dizziness—Hydroxyurea—psoriasis	0.000446	0.00169	CcSEcCtD
Perhexiline—Hyperhidrosis—Cyclosporine—psoriasis	0.000442	0.00168	CcSEcCtD
Perhexiline—Convulsion—Prednisolone—psoriasis	0.000441	0.00168	CcSEcCtD
Perhexiline—Shock—Mycophenolate mofetil—psoriasis	0.000439	0.00167	CcSEcCtD
Perhexiline—Loss of consciousness—Hydrocortisone—psoriasis	0.000437	0.00166	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—LEP—psoriasis	0.000437	0.00696	CbGpPWpGaD
Perhexiline—Anorexia—Cyclosporine—psoriasis	0.000436	0.00166	CcSEcCtD
Perhexiline—Convulsion—Hydrocortisone—psoriasis	0.000431	0.00164	CcSEcCtD
Perhexiline—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000431	0.00164	CcSEcCtD
Perhexiline—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000429	0.00684	CbGpPWpGaD
Perhexiline—Vomiting—Hydroxyurea—psoriasis	0.000429	0.00163	CcSEcCtD
Perhexiline—CPT1A—Metabolism—NDUFA5—psoriasis	0.000426	0.00679	CbGpPWpGaD
Perhexiline—Rash—Hydroxyurea—psoriasis	0.000425	0.00162	CcSEcCtD
Perhexiline—Anorexia—Mycophenolate mofetil—psoriasis	0.000425	0.00161	CcSEcCtD
Perhexiline—Dermatitis—Hydroxyurea—psoriasis	0.000425	0.00161	CcSEcCtD
Perhexiline—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000423	0.00674	CbGpPWpGaD
Perhexiline—Headache—Hydroxyurea—psoriasis	0.000423	0.00161	CcSEcCtD
Perhexiline—Syncope—Triamcinolone—psoriasis	0.00042	0.0016	CcSEcCtD
Perhexiline—CPT1A—AMPK Signaling—TP53—psoriasis	0.000419	0.00667	CbGpPWpGaD
Perhexiline—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000416	0.00662	CbGpPWpGaD
Perhexiline—Insomnia—Cyclosporine—psoriasis	0.000413	0.00157	CcSEcCtD
Perhexiline—Loss of consciousness—Triamcinolone—psoriasis	0.000412	0.00157	CcSEcCtD
Perhexiline—Paraesthesia—Cyclosporine—psoriasis	0.00041	0.00156	CcSEcCtD
Perhexiline—Shock—Prednisolone—psoriasis	0.000409	0.00155	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—NOS2—psoriasis	0.000407	0.00648	CbGpPWpGaD
Perhexiline—Convulsion—Triamcinolone—psoriasis	0.000406	0.00154	CcSEcCtD
Perhexiline—Asthenia—Mycophenolic acid—psoriasis	0.000405	0.00154	CcSEcCtD
Perhexiline—Insomnia—Mycophenolate mofetil—psoriasis	0.000403	0.00153	CcSEcCtD
Perhexiline—Hyperhidrosis—Prednisolone—psoriasis	0.000402	0.00153	CcSEcCtD
Perhexiline—Nausea—Hydroxyurea—psoriasis	0.000401	0.00152	CcSEcCtD
Perhexiline—Paraesthesia—Mycophenolate mofetil—psoriasis	0.0004	0.00152	CcSEcCtD
Perhexiline—Shock—Hydrocortisone—psoriasis	0.0004	0.00152	CcSEcCtD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000398	0.00633	CbGpPWpGaD
Perhexiline—Decreased appetite—Cyclosporine—psoriasis	0.000397	0.00151	CcSEcCtD
Perhexiline—Flushing—Prednisone—psoriasis	0.000395	0.0015	CcSEcCtD
Perhexiline—Fatigue—Cyclosporine—psoriasis	0.000394	0.0015	CcSEcCtD
Perhexiline—Hyperhidrosis—Hydrocortisone—psoriasis	0.000393	0.00149	CcSEcCtD
Perhexiline—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000388	0.00147	CcSEcCtD
Perhexiline—Anorexia—Hydrocortisone—psoriasis	0.000387	0.00147	CcSEcCtD
Perhexiline—Syncope—Dexamethasone—psoriasis	0.000381	0.00145	CcSEcCtD
Perhexiline—Syncope—Betamethasone—psoriasis	0.000381	0.00145	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—PPARG—psoriasis	0.000381	0.00606	CbGpPWpGaD
Perhexiline—Sweating—Methotrexate—psoriasis	0.00038	0.00144	CcSEcCtD
Perhexiline—Shock—Triamcinolone—psoriasis	0.000376	0.00143	CcSEcCtD
Perhexiline—Insomnia—Prednisolone—psoriasis	0.000376	0.00143	CcSEcCtD
Perhexiline—Gastrointestinal pain—Cyclosporine—psoriasis	0.000374	0.00142	CcSEcCtD
Perhexiline—Loss of consciousness—Dexamethasone—psoriasis	0.000374	0.00142	CcSEcCtD
Perhexiline—Loss of consciousness—Betamethasone—psoriasis	0.000374	0.00142	CcSEcCtD
Perhexiline—Dizziness—Mycophenolic acid—psoriasis	0.000374	0.00142	CcSEcCtD
Perhexiline—Paraesthesia—Prednisolone—psoriasis	0.000373	0.00142	CcSEcCtD
Perhexiline—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000373	0.00594	CbGpPWpGaD
Perhexiline—Hyperhidrosis—Triamcinolone—psoriasis	0.00037	0.0014	CcSEcCtD
Perhexiline—Convulsion—Dexamethasone—psoriasis	0.000368	0.0014	CcSEcCtD
Perhexiline—Convulsion—Betamethasone—psoriasis	0.000368	0.0014	CcSEcCtD
Perhexiline—Insomnia—Hydrocortisone—psoriasis	0.000367	0.0014	CcSEcCtD
Perhexiline—Paraesthesia—Hydrocortisone—psoriasis	0.000365	0.00139	CcSEcCtD
Perhexiline—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000365	0.00139	CcSEcCtD
Perhexiline—Urticaria—Cyclosporine—psoriasis	0.000363	0.00138	CcSEcCtD
Perhexiline—CPT1A—Metabolism—CYP2S1—psoriasis	0.000363	0.00578	CbGpPWpGaD
Perhexiline—Abdominal pain—Cyclosporine—psoriasis	0.000361	0.00137	CcSEcCtD
Perhexiline—Vomiting—Mycophenolic acid—psoriasis	0.000359	0.00136	CcSEcCtD
Perhexiline—Rash—Mycophenolic acid—psoriasis	0.000356	0.00135	CcSEcCtD
Perhexiline—Dermatitis—Mycophenolic acid—psoriasis	0.000356	0.00135	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000356	0.00566	CbGpPWpGaD
Perhexiline—Hepatitis—Methotrexate—psoriasis	0.000355	0.00135	CcSEcCtD
Perhexiline—Urticaria—Mycophenolate mofetil—psoriasis	0.000354	0.00135	CcSEcCtD
Perhexiline—Headache—Mycophenolic acid—psoriasis	0.000354	0.00134	CcSEcCtD
Perhexiline—Decreased appetite—Hydrocortisone—psoriasis	0.000353	0.00134	CcSEcCtD
Perhexiline—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000352	0.00134	CcSEcCtD
Perhexiline—Fatigue—Hydrocortisone—psoriasis	0.00035	0.00133	CcSEcCtD
Perhexiline—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000349	0.00555	CbGpPWpGaD
Perhexiline—Insomnia—Triamcinolone—psoriasis	0.000346	0.00131	CcSEcCtD
Perhexiline—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000344	0.00548	CbGpPWpGaD
Perhexiline—Paraesthesia—Triamcinolone—psoriasis	0.000343	0.0013	CcSEcCtD
Perhexiline—Shock—Dexamethasone—psoriasis	0.000341	0.0013	CcSEcCtD
Perhexiline—Shock—Betamethasone—psoriasis	0.000341	0.0013	CcSEcCtD
Perhexiline—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000338	0.00539	CbGpPWpGaD
Perhexiline—Nausea—Mycophenolic acid—psoriasis	0.000336	0.00128	CcSEcCtD
Perhexiline—Hyperhidrosis—Betamethasone—psoriasis	0.000335	0.00127	CcSEcCtD
Perhexiline—Hyperhidrosis—Dexamethasone—psoriasis	0.000335	0.00127	CcSEcCtD
Perhexiline—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000332	0.00126	CcSEcCtD
Perhexiline—Syncope—Prednisone—psoriasis	0.000332	0.00126	CcSEcCtD
Perhexiline—Anorexia—Dexamethasone—psoriasis	0.000331	0.00126	CcSEcCtD
Perhexiline—Anorexia—Betamethasone—psoriasis	0.000331	0.00126	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—JUN—psoriasis	0.000331	0.00526	CbGpPWpGaD
Perhexiline—Urticaria—Prednisolone—psoriasis	0.00033	0.00126	CcSEcCtD
Perhexiline—Fatigue—Triamcinolone—psoriasis	0.00033	0.00125	CcSEcCtD
Perhexiline—Asthenia—Cyclosporine—psoriasis	0.000328	0.00125	CcSEcCtD
Perhexiline—Loss of consciousness—Prednisone—psoriasis	0.000325	0.00124	CcSEcCtD
Perhexiline—Urticaria—Hydrocortisone—psoriasis	0.000323	0.00123	CcSEcCtD
Perhexiline—Abdominal pain—Hydrocortisone—psoriasis	0.000321	0.00122	CcSEcCtD
Perhexiline—Convulsion—Prednisone—psoriasis	0.000321	0.00122	CcSEcCtD
Perhexiline—Asthenia—Mycophenolate mofetil—psoriasis	0.00032	0.00122	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000318	0.00507	CbGpPWpGaD
Perhexiline—Insomnia—Dexamethasone—psoriasis	0.000314	0.00119	CcSEcCtD
Perhexiline—Insomnia—Betamethasone—psoriasis	0.000314	0.00119	CcSEcCtD
Perhexiline—Paraesthesia—Dexamethasone—psoriasis	0.000312	0.00118	CcSEcCtD
Perhexiline—Paraesthesia—Betamethasone—psoriasis	0.000312	0.00118	CcSEcCtD
Perhexiline—Urticaria—Triamcinolone—psoriasis	0.000304	0.00115	CcSEcCtD
Perhexiline—Dizziness—Cyclosporine—psoriasis	0.000302	0.00115	CcSEcCtD
Perhexiline—Decreased appetite—Betamethasone—psoriasis	0.000302	0.00115	CcSEcCtD
Perhexiline—Decreased appetite—Dexamethasone—psoriasis	0.000302	0.00115	CcSEcCtD
Perhexiline—Fatigue—Dexamethasone—psoriasis	0.000299	0.00114	CcSEcCtD
Perhexiline—Fatigue—Betamethasone—psoriasis	0.000299	0.00114	CcSEcCtD
Perhexiline—Shock—Prednisone—psoriasis	0.000297	0.00113	CcSEcCtD
Perhexiline—Dizziness—Mycophenolate mofetil—psoriasis	0.000295	0.00112	CcSEcCtD
Perhexiline—Hyperhidrosis—Prednisone—psoriasis	0.000292	0.00111	CcSEcCtD
Perhexiline—Asthenia—Hydrocortisone—psoriasis	0.000291	0.00111	CcSEcCtD
Perhexiline—Vomiting—Cyclosporine—psoriasis	0.000291	0.0011	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000289	0.0046	CbGpPWpGaD
Perhexiline—Rash—Cyclosporine—psoriasis	0.000288	0.00109	CcSEcCtD
Perhexiline—Anorexia—Prednisone—psoriasis	0.000288	0.00109	CcSEcCtD
Perhexiline—Dermatitis—Cyclosporine—psoriasis	0.000288	0.00109	CcSEcCtD
Perhexiline—Headache—Cyclosporine—psoriasis	0.000286	0.00109	CcSEcCtD
Perhexiline—Gastrointestinal pain—Betamethasone—psoriasis	0.000284	0.00108	CcSEcCtD
Perhexiline—Gastrointestinal pain—Dexamethasone—psoriasis	0.000284	0.00108	CcSEcCtD
Perhexiline—Vomiting—Mycophenolate mofetil—psoriasis	0.000283	0.00108	CcSEcCtD
Perhexiline—Rash—Mycophenolate mofetil—psoriasis	0.000281	0.00107	CcSEcCtD
Perhexiline—Dermatitis—Mycophenolate mofetil—psoriasis	0.000281	0.00107	CcSEcCtD
Perhexiline—Headache—Mycophenolate mofetil—psoriasis	0.000279	0.00106	CcSEcCtD
Perhexiline—Urticaria—Betamethasone—psoriasis	0.000276	0.00105	CcSEcCtD
Perhexiline—Urticaria—Dexamethasone—psoriasis	0.000276	0.00105	CcSEcCtD
Perhexiline—Dizziness—Prednisolone—psoriasis	0.000275	0.00105	CcSEcCtD
Perhexiline—Asthenia—Triamcinolone—psoriasis	0.000274	0.00104	CcSEcCtD
Perhexiline—Abdominal pain—Dexamethasone—psoriasis	0.000274	0.00104	CcSEcCtD
Perhexiline—Abdominal pain—Betamethasone—psoriasis	0.000274	0.00104	CcSEcCtD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000274	0.00437	CbGpPWpGaD
Perhexiline—Insomnia—Prednisone—psoriasis	0.000273	0.00104	CcSEcCtD
Perhexiline—Nausea—Cyclosporine—psoriasis	0.000271	0.00103	CcSEcCtD
Perhexiline—Paraesthesia—Prednisone—psoriasis	0.000271	0.00103	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—JUN—psoriasis	0.00027	0.0043	CbGpPWpGaD
Perhexiline—Dizziness—Hydrocortisone—psoriasis	0.000269	0.00102	CcSEcCtD
Perhexiline—Convulsion—Methotrexate—psoriasis	0.000268	0.00102	CcSEcCtD
Perhexiline—Nausea—Mycophenolate mofetil—psoriasis	0.000265	0.00101	CcSEcCtD
Perhexiline—Decreased appetite—Prednisone—psoriasis	0.000263	0.000998	CcSEcCtD
Perhexiline—Rash—Prednisolone—psoriasis	0.000262	0.000996	CcSEcCtD
Perhexiline—Dermatitis—Prednisolone—psoriasis	0.000262	0.000995	CcSEcCtD
Perhexiline—Fatigue—Prednisone—psoriasis	0.000261	0.00099	CcSEcCtD
Perhexiline—Headache—Prednisolone—psoriasis	0.000261	0.00099	CcSEcCtD
Perhexiline—Vomiting—Hydrocortisone—psoriasis	0.000258	0.000981	CcSEcCtD
Perhexiline—Rash—Hydrocortisone—psoriasis	0.000256	0.000973	CcSEcCtD
Perhexiline—Dermatitis—Hydrocortisone—psoriasis	0.000256	0.000972	CcSEcCtD
Perhexiline—CPT2—Metabolism—CARM1—psoriasis	0.000255	0.00407	CbGpPWpGaD
Perhexiline—Headache—Hydrocortisone—psoriasis	0.000254	0.000967	CcSEcCtD
Perhexiline—Dizziness—Triamcinolone—psoriasis	0.000253	0.000961	CcSEcCtD
Perhexiline—Asthenia—Dexamethasone—psoriasis	0.000249	0.000946	CcSEcCtD
Perhexiline—Asthenia—Betamethasone—psoriasis	0.000249	0.000946	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—TNF—psoriasis	0.000248	0.00394	CbGpPWpGaD
Perhexiline—Gastrointestinal pain—Prednisone—psoriasis	0.000247	0.000939	CcSEcCtD
Perhexiline—Nausea—Prednisolone—psoriasis	0.000247	0.000939	CcSEcCtD
Perhexiline—Hyperhidrosis—Methotrexate—psoriasis	0.000244	0.000928	CcSEcCtD
Perhexiline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000243	0.00387	CbGpPWpGaD
Perhexiline—Vomiting—Triamcinolone—psoriasis	0.000243	0.000924	CcSEcCtD
Perhexiline—Nausea—Hydrocortisone—psoriasis	0.000241	0.000917	CcSEcCtD
Perhexiline—Rash—Triamcinolone—psoriasis	0.000241	0.000916	CcSEcCtD
Perhexiline—Dermatitis—Triamcinolone—psoriasis	0.000241	0.000915	CcSEcCtD
Perhexiline—Anorexia—Methotrexate—psoriasis	0.000241	0.000915	CcSEcCtD
Perhexiline—Urticaria—Prednisone—psoriasis	0.00024	0.000912	CcSEcCtD
Perhexiline—Headache—Triamcinolone—psoriasis	0.00024	0.00091	CcSEcCtD
Perhexiline—Abdominal pain—Prednisone—psoriasis	0.000239	0.000908	CcSEcCtD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000239	0.0038	CbGpPWpGaD
Perhexiline—Dizziness—Betamethasone—psoriasis	0.000229	0.000872	CcSEcCtD
Perhexiline—Dizziness—Dexamethasone—psoriasis	0.000229	0.000872	CcSEcCtD
Perhexiline—Insomnia—Methotrexate—psoriasis	0.000228	0.000868	CcSEcCtD
Perhexiline—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000228	0.00363	CbGpPWpGaD
Perhexiline—Nausea—Triamcinolone—psoriasis	0.000227	0.000863	CcSEcCtD
Perhexiline—Paraesthesia—Methotrexate—psoriasis	0.000227	0.000862	CcSEcCtD
Perhexiline—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000225	0.00358	CbGpPWpGaD
Perhexiline—Vomiting—Betamethasone—psoriasis	0.000221	0.000838	CcSEcCtD
Perhexiline—Vomiting—Dexamethasone—psoriasis	0.000221	0.000838	CcSEcCtD
Perhexiline—Decreased appetite—Methotrexate—psoriasis	0.00022	0.000834	CcSEcCtD
Perhexiline—Rash—Betamethasone—psoriasis	0.000219	0.000831	CcSEcCtD
Perhexiline—Rash—Dexamethasone—psoriasis	0.000219	0.000831	CcSEcCtD
Perhexiline—Dermatitis—Dexamethasone—psoriasis	0.000219	0.000831	CcSEcCtD
Perhexiline—Dermatitis—Betamethasone—psoriasis	0.000219	0.000831	CcSEcCtD
Perhexiline—Fatigue—Methotrexate—psoriasis	0.000218	0.000827	CcSEcCtD
Perhexiline—Headache—Dexamethasone—psoriasis	0.000217	0.000826	CcSEcCtD
Perhexiline—Headache—Betamethasone—psoriasis	0.000217	0.000826	CcSEcCtD
Perhexiline—Asthenia—Prednisone—psoriasis	0.000217	0.000824	CcSEcCtD
Perhexiline—Gastrointestinal pain—Methotrexate—psoriasis	0.000207	0.000785	CcSEcCtD
Perhexiline—Nausea—Betamethasone—psoriasis	0.000206	0.000783	CcSEcCtD
Perhexiline—Nausea—Dexamethasone—psoriasis	0.000206	0.000783	CcSEcCtD
Perhexiline—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000201	0.0032	CbGpPWpGaD
Perhexiline—Urticaria—Methotrexate—psoriasis	0.000201	0.000762	CcSEcCtD
Perhexiline—Dizziness—Prednisone—psoriasis	0.0002	0.000759	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—IL6—psoriasis	0.0002	0.00318	CbGpPWpGaD
Perhexiline—Abdominal pain—Methotrexate—psoriasis	0.0002	0.000759	CcSEcCtD
Perhexiline—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000197	0.00313	CbGpPWpGaD
Perhexiline—Vomiting—Prednisone—psoriasis	0.000192	0.00073	CcSEcCtD
Perhexiline—Rash—Prednisone—psoriasis	0.000191	0.000724	CcSEcCtD
Perhexiline—Dermatitis—Prednisone—psoriasis	0.00019	0.000723	CcSEcCtD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.00019	0.00303	CbGpPWpGaD
Perhexiline—Headache—Prednisone—psoriasis	0.000189	0.000719	CcSEcCtD
Perhexiline—Asthenia—Methotrexate—psoriasis	0.000181	0.000689	CcSEcCtD
Perhexiline—Nausea—Prednisone—psoriasis	0.000179	0.000682	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—TP53—psoriasis	0.000178	0.00284	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—CARM1—psoriasis	0.000177	0.00282	CbGpPWpGaD
Perhexiline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00017	0.0027	CbGpPWpGaD
Perhexiline—Dizziness—Methotrexate—psoriasis	0.000167	0.000635	CcSEcCtD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000166	0.00264	CbGpPWpGaD
Perhexiline—CPT1A—Circadian rythm related genes—IL6—psoriasis	0.000163	0.0026	CbGpPWpGaD
Perhexiline—Vomiting—Methotrexate—psoriasis	0.000161	0.00061	CcSEcCtD
Perhexiline—Rash—Methotrexate—psoriasis	0.000159	0.000605	CcSEcCtD
Perhexiline—Dermatitis—Methotrexate—psoriasis	0.000159	0.000605	CcSEcCtD
Perhexiline—Headache—Methotrexate—psoriasis	0.000158	0.000601	CcSEcCtD
Perhexiline—CPT2—Metabolism—CAT—psoriasis	0.000157	0.0025	CbGpPWpGaD
Perhexiline—Nausea—Methotrexate—psoriasis	0.00015	0.00057	CcSEcCtD
Perhexiline—CPT2—Metabolism—APOE—psoriasis	0.000122	0.00194	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—CAT—psoriasis	0.000109	0.00173	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—PPARG—psoriasis	0.000106	0.00169	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—NDUFA5—psoriasis	0.000101	0.00161	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—CYP2S1—psoriasis	8.58e-05	0.00137	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—APOE—psoriasis	8.46e-05	0.00135	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—PPARG—psoriasis	7.37e-05	0.00117	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—NDUFA5—psoriasis	7.01e-05	0.00112	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—CYP2S1—psoriasis	5.96e-05	0.00095	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—NDUFA5—psoriasis	4.59e-05	0.00073	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—CARM1—psoriasis	4.19e-05	0.000667	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—CYP2S1—psoriasis	3.9e-05	0.000621	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—CARM1—psoriasis	2.91e-05	0.000464	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—CAT—psoriasis	2.58e-05	0.000411	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—APOE—psoriasis	2e-05	0.000319	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—CARM1—psoriasis	1.9e-05	0.000303	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—CAT—psoriasis	1.79e-05	0.000285	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—PPARG—psoriasis	1.74e-05	0.000278	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—APOE—psoriasis	1.39e-05	0.000222	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—PPARG—psoriasis	1.21e-05	0.000193	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—CAT—psoriasis	1.17e-05	0.000187	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—APOE—psoriasis	9.1e-06	0.000145	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—PPARG—psoriasis	7.93e-06	0.000126	CbGpPWpGaD
